Drug distributor Cardinal Health to lose OptumRx contracts
“Today’s announcement was a worst-case scenario for Cardinal Health’s Optum renewal,” EvercoreISI analyst Elizabeth Anderson wrote in a note.
If you are not happy with the results below please do another search
“Today’s announcement was a worst-case scenario for Cardinal Health’s Optum renewal,” EvercoreISI analyst Elizabeth Anderson wrote in a note.
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
Could stem cell therapies make the Parkinsonian brain generate dopamine again? Some companies, including BlueRock Therapeutics and International Stem Cell Corporation, are banking on it.
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
CVS Health has lost a bid to escape a proposed class action lawsuit accusing the company of discriminating against people with HIV by requiring them to receive their medications by mail.
Though a Sanofi spokesperson declined to provide details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they said that the changes are part of Sanofi’s push to implement “a streamlined strategic sales structure.”
Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.
Following a months-long safety review, the regulator said it is now requiring black box warnings for all commercially available CAR-T therapies to reflect the risk of secondary malignancies.
The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children’s cough syrup found in Nigeria last week, it said in an email.
Drug maker Vifor Pharma has offered to rectify its disparaging campaign against the closest rival to its blockbuster iron deficiency medicine Ferinject, EU antitrust regulators said on Friday, a move that would stave off a potential hefty fine and end an antitrust investigation.